According to the National Cancer Comprehensive Network, the criteria for determining postmenopausal breast cancer include prior bilateral oophorectomy, >60, <60 years and amenorrhoea for ≥12 months in the absence of chemotherapy, TAM, toremifene, or ovarian suppression, and postmenopausal range of FSH and E2 levels; if a patient <60 years is taking TAM or toremifene, the FSH and E2 levels should be in the postmenopausal range (National Comprehensive Cancer Network 2013). Here, BRD2 is linked to breast cancer.